-
Mashup Score: 312023 ESC Guidelines for Managing CVD in Diabetes: Key Points—Part 2 - American College of Cardiology - 8 month(s) ago
Melvyn Rubenfire, MD, FACC
Source: www.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 36Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction: - 8 month(s) ago
Abstract Background It is unknown how the efficacy and safety of mineralocorticoid receptor antagonists vary according to duration of heart failure with reduced ejection fraction (HFrEF). Objective…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
In #HFrEF, adding mineralocorticoid antagonists was always beneficial, and most beneficial the longer patients used them, a new #JACC study suggests: https://t.co/JbD2XW3cbk #CardioTwitter @UoGHeartFailure @PSJhund https://t.co/lT0i8tGyGn
-
-
Mashup Score: 0‘It is rarely too late’ to initiate eplerenone for HFrEF - 8 month(s) ago
Initiation of the nonsteroidal mineralocorticoid receptor antagonist eplerenone shows benefit in patients with HF with reduced ejection fraction, regardless of their disease duration, 1 year or more than 5 years, a speaker reported. A post hoc analysis of the EMPHASIS-HF trial was presented at the European Society of Cardiology Congress and simultaneously published in the Journal of the American
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Initiation of the nonsteroidal MRA #eplerenone shows benefit in patients with #HFrEF, regardless of their disease duration, 1 year or more than 5 years @ACCinTouch #ESCCongress @ESCardioNews #cardiotwitter https://t.co/skyuTvizzI
-
-
Mashup Score: 0Sex Differences in long‐term outcomes following acute heart failure hospitalization: Findings from the Get with The Guidelines ‐ Heart Failure Registry - 8 month(s) ago
Background and Aims Sex differences in long-term outcomes following hospitalization for heart failure (HF) across ejection fraction (EF) subtypes are not well described. In this study, we evaluated …
Source: onlinelibrary.wiley.comCategories: Cardiologists, Latest HeadlinesTweet-
In #GWTG analysis of #SexDifferences 5y following #HF🏥, led by @ambarish4786 F (vs M) had 🔺lower risk of ☠️, w risk diff greatest in #HFrEF 🔺higher risk of HF rehosp, w risk diff greatest in #HFpEF 🔺more years of life lost than age/sex matched pop’n https://t.co/6WMKNGqOti https://t.co/pPtcmj8GTA
-
-
Mashup Score: 0Traditional Chinese Medicine Improves Outcomes in HFrEF - 8 month(s) ago
In the randomized trial QUEST trial, a traditional Chinese medicine called qiliqiangxin provided significant reductions in CV death and hospitalization on top of guideline-directed therapy in HFrEF.
Source: www.medscape.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In the randomized trial QUEST trial, a traditional Chinese medicine called #qiliqiangxin provided significant reductions in CV death and hospitalization on top of guideline-directed therapy in #HFrEF. #ESCCongress https://t.co/aNOJKKcz5H
-
-
Mashup Score: 0Traditional Chinese Medicine Improves Outcomes in HFrEF - 8 month(s) ago
In the randomized trial QUEST trial, a traditional Chinese medicine called qiliqiangxin provided significant reductions in CV death and hospitalization on top of guideline-directed therapy in HFrEF.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet-
In the randomized trial QUEST trial, a traditional #Chinesemedicine called #qiliqiangxin provided significant reductions in CV death and hospitalization on top of guideline-directed therapy in #HFrEF. #ESCCongress https://t.co/ofcGfb6DNo
-
-
Mashup Score: 0Traditional Chinese Medicine Improves Outcomes in HFrEF - 8 month(s) ago
In the randomized trial QUEST trial, a traditional Chinese medicine called qiliqiangxin provided significant reductions in CV death and hospitalization on top of guideline-directed therapy in HFrEF.
Source: www.medscape.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In the randomized trial QUEST trial, a traditional #Chinesemedicine called qiliqiangxin provided significant reductions in CV death and hospitalization on top of guideline-directed therapy in #HFrEF. #ESCCongress https://t.co/rL4xM2gXmp
-
-
Mashup Score: 4Heart Failure & SGLT2is: The New Pillar in Care - 9 month(s) ago
Heart Failure & SGLT2is: The New Pillar in Care What You Will Learn Current heart failure patient management challenges How to distinguish pathophysiologic characteristics of HF Guideline-directed…
Source: learn.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Learn current challenges for #heartfailure patients, ❓ to distinguish pathophysiologic characteristics of heart failure, GDMT, & customizing treatment plans for #HFrEF & #HFpEF patients w/ ACC's Heart Failure & #SGLT2is 💻 course. 🔗 https://t.co/nIX2CbC840 #ESCCongress #ACCEd https://t.co/xrKg8qHcGQ
-
-
Mashup Score: 19Opportunities and Achievement of Medication Initiation Among Inpatients With Heart Failure With Reduced Ejection Fraction: - 9 month(s) ago
Abstract Background Initiation of evidence-based medications for patients with heart failure with reduced ejection fraction (HFrEF) during hospitalization in contemporary practice is unknown. Objec…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
More than 4 in 5 patients admitted with #HFrEF can benefit from medication optimization before hospital discharge. Check out the article in this month's issue of #JACCHF to learn more: https://t.co/w9Af4PsP4C #HeartFailure #QoL #CardioTwitter https://t.co/OREnSbpokF
-
-
Mashup Score: 5Immunometabolism at the Heart of Cardiovascular Disease: - 9 month(s) ago
Highlights • Cardiac leukocytes are regulated by cell-intrinsic shifts in metabolism, which in turn modulate heart function. • Both innate and adaptive cardiac immune cells are uniquely regulated b…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
Immunometabolism during #HFrEF, cardiometabolic disease & #HFpEF in #JACCBTS: Dr. @Matt_DeBerge, et al. discuss protective or pathologic roles for metabolic signaling in myeloid cells & lymphocytes & its therapeutic implications for #cvMI & #HeartFailure: https://t.co/eyS2LadTip https://t.co/Dj1vuiEuhf
-
🔑 SGLT2 inhibitors are recommended in all patients w/ #HFrEF & T2DM to reduce the risk of HF hospitalization & CV death. Read key points to remember from the 2023 ESC guidelines for the management of CVD in patients w/ diabetes, part 2 of 2: https://t.co/kLXZz1lnjC #diabetes